AU2002225895A1 - Hepatitis c virus constructs characterized by high efficiency replication - Google Patents

Hepatitis c virus constructs characterized by high efficiency replication

Info

Publication number
AU2002225895A1
AU2002225895A1 AU2002225895A AU2589502A AU2002225895A1 AU 2002225895 A1 AU2002225895 A1 AU 2002225895A1 AU 2002225895 A AU2002225895 A AU 2002225895A AU 2589502 A AU2589502 A AU 2589502A AU 2002225895 A1 AU2002225895 A1 AU 2002225895A1
Authority
AU
Australia
Prior art keywords
hepatitis
high efficiency
virus constructs
constructs characterized
replication
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002225895A
Inventor
Vadim Bichko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anadys Pharmaceuticals Inc
Original Assignee
Anadys Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anadys Pharmaceuticals Inc filed Critical Anadys Pharmaceuticals Inc
Publication of AU2002225895A1 publication Critical patent/AU2002225895A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/18Togaviridae; Flaviviridae
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00Immunoassays for the detection of microorganisms
    • G01N2469/20Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002225895A 2000-11-07 2001-11-02 Hepatitis c virus constructs characterized by high efficiency replication Abandoned AU2002225895A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24586600P 2000-11-07 2000-11-07
US60/245,866 2000-11-07
PCT/US2001/046350 WO2002038793A2 (en) 2000-11-07 2001-11-02 Hepatitis c virus constructs characterized by high efficiency replication

Publications (1)

Publication Number Publication Date
AU2002225895A1 true AU2002225895A1 (en) 2002-05-21

Family

ID=22928409

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002225895A Abandoned AU2002225895A1 (en) 2000-11-07 2001-11-02 Hepatitis c virus constructs characterized by high efficiency replication

Country Status (3)

Country Link
US (2) US6930095B2 (en)
AU (1) AU2002225895A1 (en)
WO (1) WO2002038793A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6921634B2 (en) * 1999-12-23 2005-07-26 Board Of Regents, The University Of Texas System Replication competent hepatitus C virus and methods of use
JP4299540B2 (en) 2001-01-23 2009-07-22 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー Hepatitis C virus replicon and replicon enhanced cells
FR2824072B1 (en) * 2001-04-27 2004-03-12 Centre Nat Rech Scient PROCESS FOR REPLICATION AND PRODUCTION OF HEPATITIS C VIRUS
DE602004024658D1 (en) 2003-02-13 2010-01-28 Merck & Co Inc METHOD FOR TRANSFERRING CELL CULTURAL REPLICATION ACTIVITY TO DIFFERENT HEPATITIS C VIRUS ISOLATES
US8354518B2 (en) 2003-11-05 2013-01-15 Merck Sharp & Dohme Corp. HCV replicons containing NS5B from genotype 2B
DK2423216T3 (en) * 2003-12-01 2015-07-20 Univ Texas Replication-competent hepatitis C virus and methods of using
CU23496A1 (en) * 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech VACCINE COMPOSITION AGAINST THE VIRUS OF HEPATITIS C
EP1801116A1 (en) * 2005-12-21 2007-06-27 F. Hoffmann-La Roche Ag HCV replicon shuttle vectors
CN100371022C (en) * 2006-05-10 2008-02-27 李卫云 Method for establishing anti-hepatitis C virus drug screening experimental animal model
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
US20100173281A1 (en) * 2009-01-06 2010-07-08 Roche Palo Alto Llc HCV NS3 protease replicon shuttle vectors
EP3201342A4 (en) 2014-10-01 2018-07-25 National Research Council of Canada Animal models, cell lines and methods for screening hepatitis c virus vaccines
CN106939300A (en) * 2017-04-26 2017-07-11 中国医学科学院医学生物学研究所 Tree shrew immortalized liver cell cell line and its construction method and application
CN107312856B (en) * 2017-07-24 2020-10-27 广州医科大学附属第一医院 Primer pair, probe, kit and method for detecting common infection-related cytokines of tree shrew by fluorescent quantitative PCR (polymerase chain reaction)
CN111440769B (en) * 2020-02-25 2021-07-06 浙江大学 Human hepatocyte hepatoma cell strain and application thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679342A (en) 1987-11-18 1997-10-21 Chiron Corporation Hepatitis C virus infected cell systems
US6127116A (en) 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
US5874565A (en) * 1995-08-29 1999-02-23 Washington University Nucleic acids comprising a highly conserved novel 3 terminal sequence element of the hepatitis C virus
US7049428B1 (en) * 1998-03-04 2006-05-23 Washington University HCV variants
DE19915178A1 (en) 1999-04-03 2000-10-05 Univ Mainz Johannes Gutenberg Hepatitis C virus cell culture system
MXPA03005638A (en) 2000-12-22 2004-04-05 Boehringer Ingelheim Ca Ltd Self-replicating rna molecule from hepatitis c virus.

Also Published As

Publication number Publication date
US6930095B2 (en) 2005-08-16
US20020155133A1 (en) 2002-10-24
US20050260221A1 (en) 2005-11-24
WO2002038793A3 (en) 2002-08-15
WO2002038793A9 (en) 2003-02-13
WO2002038793A2 (en) 2002-05-16

Similar Documents

Publication Publication Date Title
AU2001282528A1 (en) Compounds having anti-hepatitis c virus effect
AU2002210450A1 (en) Maintaining virus detection software
AU2002225895A1 (en) Hepatitis c virus constructs characterized by high efficiency replication
AU2003206862A1 (en) Hepatitis b vaccines
AU7087901A (en) Modified virus
AU2001238401A1 (en) Cold-adapted equine influenza viruses
AU2003294757A1 (en) Formulations useful against hepatitis c virus infections
AU2002306709A1 (en) Oncolytic rna replicons
AU2001278337A1 (en) Respiratory syncytial virus vaccine
AU2002243257A1 (en) Oncolytic virus
AU2002257890A1 (en) Method for replicating the hepatitis C virus
AUPR160400A0 (en) Plant virus promoter
GB0001475D0 (en) Virus strains
GB0001476D0 (en) Herpes virus strains
AU2003301865A1 (en) Epitopes of hepatitis c virus
AU2003248821A1 (en) Chimeric gb virus b (gbv-b)
AU2003227026A1 (en) An infectious bursal disease virus variant
AU2001286111A1 (en) Improvements to lasers
AU6551800A (en) Dinucleoside 5',5'-tetraphosphates as inhibitors of viral reverse transcriptasesand viruses
AU2002222139A1 (en) Hcv vaccines
AU2001229677A1 (en) Recombinant rhabdoviruses as live-viral vaccines for immunodeficiency viruses
EP1290230A4 (en) Hepatitis c virus conjugates
AU2003256404A1 (en) Hepatitis c virus assays
AU2002224845A1 (en) Viral expression system
AU4957800A (en) Vaccine against isa virus